One drop of Miebo had no significant impact on presurgical corneal measurements taken within 60 minutes of instillation, ...

The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with Phentolamine Ophthalmic Solution 0.75% achieving a ≥15-letter improvement in ...

The effect of Phentolamine Ophthalmic Solution 0.75% increased at Day 15, with 21% of participants gaining 15 or more letters of mLCVA compared to 3% of participants given the placebo (p<0.01).

Ophthalmic BSS are sterile, isotonic, irrigating solutions used during surgical procedures of the eye.

On May 18 th, 2023, U.S. Food and Drug Administration (FDA) approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) followed by the approval of VEVYE™ (cyclosporine ...

Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye. Michelle Hessen, OD, assistant professor of ...

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, ...

The multicenter, randomized, double-masked, placebo-controlled trial will investigate the safety and efficacy of phentolamine ophthalmic solution in up to 200 patients in the U.S.

In <i>Alcon Inc v Bausch & Lomb (Australia) Pty Ltd</i>, the Federal Court has held that Bausch & Lomb (Australia) Pty Ltd had infringed Alcon Inc's registration for the BSS mark by using the letters ...

A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease. Ophthalmol Sci. 2023 Dec 12;4 (3):100451. doi: 10.1016/j.xops.2023 ...